Harnessing the Natural Biology of Adeno-Associated Virus to Enhance the Efficacy of Cancer Gene Therapy

Harnessing the Natural Biology of Adeno-Associated Virus to Enhance the Efficacy of Cancer Gene Therapy

Adeno-associated virus (AAV) was first characterized as small “defective” contaminant particles in a simian adenovirus preparation in 1965. Since then, a recombinant platform of AAV (rAAV) has become one of the leading candidates for gene therapy applications resulting in two FDA-approved treatments...

Full description

Bibliographic Details
Main Authors: Jacquelyn J. Bower, Liujiang Song, Prabhakar Bastola, Matthew L. Hirsch
Format: Article
Language:English
Published: MDPI AG 2021-06-01
Series:Viruses
Subjects:
adeno-associated virus
AAV
cancer gene therapy
Online Access:https://www.mdpi.com/1999-4915/13/7/1205
id doaj-b1eb6c7c15d7421d8096e78ede3f2f76
record_format Article
spelling doaj-b1eb6c7c15d7421d8096e78ede3f2f762021-07-23T14:11:09ZengMDPI AGViruses1999-49152021-06-01131205120510.3390/v13071205Harnessing the Natural Biology of Adeno-Associated Virus to Enhance the Efficacy of Cancer Gene TherapyJacquelyn J. Bower0Liujiang Song1Prabhakar Bastola2Matthew L. Hirsch3Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC 27514, USADepartment of Ophthalmology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USADepartment of Ophthalmology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USADepartment of Ophthalmology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USAAdeno-associated virus (AAV) was first characterized as small “defective” contaminant particles in a simian adenovirus preparation in 1965. Since then, a recombinant platform of AAV (rAAV) has become one of the leading candidates for gene therapy applications resulting in two FDA-approved treatments for rare monogenic diseases and many more currently in various phases of the pharmaceutical development pipeline. Herein, we summarize rAAV approaches for the treatment of diverse types of cancers and highlight the natural anti-oncogenic effects of wild-type AAV (wtAAV), including interactions with the cellular host machinery, that are of relevance to enhance current treatment strategies for cancer.https://www.mdpi.com/1999-4915/13/7/1205adeno-associated virusAAVcancer gene therapy
collection DOAJ
language English
format Article
sources DOAJ
author Jacquelyn J. Bower
Liujiang Song
Prabhakar Bastola
Matthew L. Hirsch
spellingShingle Jacquelyn J. Bower
Liujiang Song
Prabhakar Bastola
Matthew L. Hirsch
Harnessing the Natural Biology of Adeno-Associated Virus to Enhance the Efficacy of Cancer Gene Therapy
Viruses
adeno-associated virus
AAV
cancer gene therapy
author_facet Jacquelyn J. Bower
Liujiang Song
Prabhakar Bastola
Matthew L. Hirsch
author_sort Jacquelyn J. Bower
title Harnessing the Natural Biology of Adeno-Associated Virus to Enhance the Efficacy of Cancer Gene Therapy
title_short Harnessing the Natural Biology of Adeno-Associated Virus to Enhance the Efficacy of Cancer Gene Therapy
title_full Harnessing the Natural Biology of Adeno-Associated Virus to Enhance the Efficacy of Cancer Gene Therapy
title_fullStr Harnessing the Natural Biology of Adeno-Associated Virus to Enhance the Efficacy of Cancer Gene Therapy
title_full_unstemmed Harnessing the Natural Biology of Adeno-Associated Virus to Enhance the Efficacy of Cancer Gene Therapy
title_sort harnessing the natural biology of adeno-associated virus to enhance the efficacy of cancer gene therapy
publisher MDPI AG
series Viruses
issn 1999-4915
publishDate 2021-06-01
description Adeno-associated virus (AAV) was first characterized as small “defective” contaminant particles in a simian adenovirus preparation in 1965. Since then, a recombinant platform of AAV (rAAV) has become one of the leading candidates for gene therapy applications resulting in two FDA-approved treatments for rare monogenic diseases and many more currently in various phases of the pharmaceutical development pipeline. Herein, we summarize rAAV approaches for the treatment of diverse types of cancers and highlight the natural anti-oncogenic effects of wild-type AAV (wtAAV), including interactions with the cellular host machinery, that are of relevance to enhance current treatment strategies for cancer.
topic adeno-associated virus
AAV
cancer gene therapy
url https://www.mdpi.com/1999-4915/13/7/1205
work_keys_str_mv AT jacquelynjbower harnessingthenaturalbiologyofadenoassociatedvirustoenhancetheefficacyofcancergenetherapy
AT liujiangsong harnessingthenaturalbiologyofadenoassociatedvirustoenhancetheefficacyofcancergenetherapy
AT prabhakarbastola harnessingthenaturalbiologyofadenoassociatedvirustoenhancetheefficacyofcancergenetherapy
AT matthewlhirsch harnessingthenaturalbiologyofadenoassociatedvirustoenhancetheefficacyofcancergenetherapy
_version_ 1721285440067076096

Similar Items